Skip to content
Search

Latest Stories

No decision on Air India yet, India clarifies after reports that Tata emerged winner

No decision on Air India yet, India clarifies after reports that Tata emerged winner

INDIA's finance ministry said on Friday (1) reports suggesting the government has picked a winning bid for the debt-laden state-run airline Air India were incorrect.

Earlier on Friday, Bloomberg reported that a panel of ministers accepted a proposal from officials recommending salt-to-software conglomerate Tata Sons ahead of an offer from Ajay Singh, promoter of India's airline operator Spicejet Ltd.


"Media reports indicating approval of financial bids by Government of India in the AI disinvestment case are incorrect," the ministry said in a tweet. "Media will be informed of the Government decision as and when it is taken."

Air India and Tata Sons declined to comment.

Earlier this month the finance ministry said it had received bids for the airline, but did not name the bidders.

A possible sale would come at a time the airline industry is trying to recover from the slump in travel caused by restrictions aimed at containing the coronavirus pandemic.

This would also be seen as a relief to Prime Minister Narendra Modi's government, which has been pushing to sell its entire interest in the loss-making airline.

The winning bidder would win control of Air India's 4,400 domestic and 1,800 international landing and parking slots at domestic airports, as well as 900 slots at airports overseas, including London's Heathrow Airport.

It would also get 100 per cent of the low-cost arm Air India Express and 50 per cent of AISATS, which provides cargo and ground handling services at major Indian airports.

The government loses nearly Rs 200 million ($2.7m) every day to run the national carrier, which has accumulated losses of over Rs 700 billion ($9.53 billion), officials have said.

An effort to auction a majority stake almost three years ago drew no bids, forcing the government to ease the terms. It had also extended the deadline multiple times during the pandemic.

(Reuters)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less